These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3729311)

  • 21. [New aspects of the pathogenesis and therapy of Guillain-Barré syndrome and chronic polyneuritis].
    Hartung HP; Heininger K; Toyka KV
    Nervenarzt; 1990 Apr; 61(4):197-207. PubMed ID: 2191228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monoclonal IgM autoantibody activity vis-à-vis glycoconjugates of peripheral nerves: apropos of 112 cases].
    Caudie C; Vial C; Petiot P; Bancel J; Lombard C; Gonnaud PM
    Ann Biol Clin (Paris); 2001; 59(5):567-77. PubMed ID: 11602387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy.
    Allen D; Giannopoulos K; Gray I; Gregson N; Makowska A; Pritchard J; Hughes RA
    J Peripher Nerv Syst; 2005 Jun; 10(2):174-80. PubMed ID: 15958128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycoplasma antibody in Guillain-Barré syndrome and other neurological disorders.
    Goldschmidt B; Menonna J; Fortunato J; Dowling P; Cook S
    Ann Neurol; 1980 Feb; 7(2):108-12. PubMed ID: 7369715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Guillain-Barré syndrome and acute disseminated encephalomyelitis (ADEM)].
    Hamaguchi K
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1301-7. PubMed ID: 9128388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GM 1 antibodies in Guillain-Barré syndrome: isotypes, course and clinical outcome.
    Seiser A; Pötzl G; Safoschnik G; Pichler S; Bernheimer H; Schwerer B
    Wien Klin Wochenschr; 1994; 106(6):159-63. PubMed ID: 8197746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical utility of measurement for anti-GM1 and anti-GQ1b antibodies].
    Tagawa Y; Matsumoto Y; Yuki N
    No To Shinkei; 1998 Sep; 50(9):849-53. PubMed ID: 9789308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Guillain-Barré syndrome with nerve conduction blocks at multiple common entrapment sites that rapidly disappeared after plasmapheresis].
    Susuki K; Johkura K; Kawauchi Y; Hasegawa O; Kuroiwa Y
    Rinsho Shinkeigaku; 1998 Mar; 38(3):270-2. PubMed ID: 9711129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guillain-Barré syndrome.
    Koski CL
    Neurol Clin; 1984 May; 2(2):355-66. PubMed ID: 6334227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of post-rubella Guillain-Barré syndrome associated with ulcerative colitis].
    Saito M; Hozumi I; Kawakami A; Tsuji S
    Rinsho Shinkeigaku; 1994 Nov; 34(11):1121-4. PubMed ID: 7729092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
    Yuki N; Ang CW; Koga M; Jacobs BC; van Doorn PA; Hirata K; van der Meché FG
    Ann Neurol; 2000 Mar; 47(3):314-21. PubMed ID: 10716250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a.
    Tatsumoto M; Koga M; Gilbert M; Odaka M; Hirata K; Kuwabara S; Yuki N
    J Neuroimmunol; 2006 Aug; 177(1-2):201-8. PubMed ID: 16844234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Association of IgA anti-GM1 antibody with antecedent diarrhea in patients with Guillain-Barré syndrome].
    Koga M; Yuki N; Hirata K
    Rinsho Shinkeigaku; 1997 Sep; 37(9):848-50. PubMed ID: 9431003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of Guillain-Barré syndrome with bulbar palsy and a high titer of anti-GT1a antibody].
    Hashiguchi S; Ogasawara N; Yoshino H
    Rinsho Shinkeigaku; 1997 Apr; 37(4):331-3. PubMed ID: 9248344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of antimyelin antibodies and serum demyelinating factors in most patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    McCombe PA; Pollard JD; McLeod JG
    Clin Exp Neurol; 1988; 25():53-60. PubMed ID: 3267485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmapheresis in the treatment of four cases of Guillain-Barré syndrome (acute form).
    Zerbi D; Celano I; Forlani G; Garelli S; Mosconi L; Valbonesi M
    Ital J Neurol Sci; 1981 Dec; 2(4):331-6. PubMed ID: 7333823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guillain Barre syndrome-electrodiagnostic features and therapeutic observations.
    Shankar V; Bhanu K; Sayeed ZA
    J Assoc Physicians India; 1995 Oct; 43(10):670-2. PubMed ID: 8773000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies.
    Odaka M; Yuki N; Tatsumoto M; Tateno M; Hirata K
    J Neurol; 2004 Jan; 251(1):24-9. PubMed ID: 14999485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome.
    Wanschitz J; Maier H; Lassmann H; Budka H; Berger T
    Brain; 2003 Sep; 126(Pt 9):2034-42. PubMed ID: 12847075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry.
    Oomes PG; Jacobs BC; Hazenberg MP; Bänffer JR; van der Meché FG
    Ann Neurol; 1995 Aug; 38(2):170-5. PubMed ID: 7654064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.